BIOLIFE SOLUTIONS INC (BLFS) Form 8-K — Aug 6, 2026
BioLife Solutions reported Q2 2026 revenue of $28.5 million, up 21% from $23.4 million a year earlier, led by its market-leading biopreservation media franchise. GAAP net income was $45.1 million, but that figure includes a $42.4 million non-cash income tax benefit from a valuation allowance release; underlying adjusted net income was $4.2 million. Adjusted EBITDA came in at $7.4 million, or 26% of revenue, versus $5.6 million a year ago, and cash, cash equivalents, and marketable securities stood at $113.1 million at June 30, 2026. The company said its biopreservation media is used in roughly 250 ongoing commercially sponsored clinical trials with more than 70% market share.
Key figures
- Eps
- 0.92
- Revenue
- 28466000
- Net Income
- 45104000
- Revenue Yoy
- 21%
- Total Assets
- 447494000
- Cash Position
- 113070000
- Deal Value Usd
- $1.5 billion (Repligen enterprise value for BioLife)
- Adjusted EBITDA
- $7.4 million (26% of revenue)
- Gross Margin GAAP
- 64%
- Six Month Revenue
- $56.0 million (up 23% YoY)
- Adjusted Net Income
- $4.2 million
- Non Cash Tax Benefit
- $42.4 million (valuation allowance release, $0.87 per share impact)
- Adjusted Gross Margin
- 65%
- Clinical Trials Served
- approximately 250 commercially sponsored trials, >70% market share
- Commercial CGTs Embedded
- 18 unique commercial CGTs as of June 30, 2026
- Six Month Adjusted EBITDA
- $13.5 million
- Deal Consideration Per Share
- $11.25 cash + 0.1442 Repligen shares per BioLife share
Price after filing
Close on the filing date to close N calendar days later (from $32.52). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.